Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...
TD Cowen analysts estimate that about 45% of U.S. sales for Ozempic and Rybelsus each goes through Medicare Part D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback